Akebia Therapeutics, Inc. (NASDAQ:AKBA) has a beta value of 1.93 and has seen 2,334,818 shares traded in the recent trading session. The company, currently valued at $431.45 Million, closed the recent trade at $2.99 per share which meant it lost -$0.06 on the day or -1.97% during that session. The AKBA stock price is -358.53% off its 52-week high price of $13.71 and 30.1% above the 52-week low of $2.09. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.41 Million shares traded. The 3-month trading volume is 6.32 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The consensus among analysts is that Akebia Therapeutics, Inc. (AKBA) is an Overweight stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 7 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.4.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information

Despite being -1.97% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jan 11 when the AKBA stock price touched $3.15-3 or saw a rise of 3.97%. Year-to-date, Akebia Therapeutics, Inc. shares have moved 8.04%, while the 5-day performance has seen it change 1.17%. Over the past 30 days, the shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) have changed 5.4%. Short interest in the company has seen 23.73 Million shares shorted with days to cover at 3.75.

Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 134.11% from current levels. The projected low price target is $3 while the price target rests at a high of $10. In that case, then, we find that the latest price level in today’s session is +234.45% off the targeted high while a plunge would see the stock lose 0.33% from current levels.

Akebia Therapeutics, Inc. (AKBA) estimates and forecasts

Figures show that Akebia Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -74.39% over the past 6 months, with this year growth rate of -10.59%, compared to 15.6% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 49.4% and 31.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be -13.9%.

6 analysts offering their estimates for the company have set an average revenue estimate of $58.49 Million for the current quarter. 4 have an estimated revenue figure of $48.31 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $69.56 Million for this quarter, and analysts expect sales will grow by -15.9% for the current quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +21.7% over the past 5 years. Earnings growth for 2021 is a modest +4.5%.

Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders

Insiders own 1.09% of the company shares, while shares held by institutions stand at 78.78% with a share float percentage of 79.64%. Investors are also buoyed by the number of investors in a company, with Akebia Therapeutics, Inc. having a total of 226 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 15.34 Million shares worth more than $38.5 Million. As of September 29, 2020, State Street Corporation held 10.61% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 11.74 Million shares as of September 29, 2020. The firm’s total holdings are worth over $29.48 Million and represent 8.13% of shares outstanding.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of December 30, 2020, the former fund manager holds about 13.66% shares in the company for having 19737122 shares of worth $55.26 Million while later fund manager owns 3.31 Million shares of worth $8.31 Million as of September 29, 2020, which makes it owner of about 2.29% of company’s outstanding stock.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
.

Sponsored


Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here